aclidinium Articles

Mixed results for Almirall and Forest's LAMA/LABA combo for COPD

2 May 2013

Added benefit of Almirall's aclidinium bromide is not proven, says Germany's IQWiG

10 January 2013

Almirall out-licenses aclidinium to Invida for Australia and New Zealand

12 October 2012

Almirall sets up first direct North America presence

5 September 2012

Credit Suisse focus on new drugs for COPD

19 August 2012

Almirall first-half sales and earnings fall, but aclidinium milestones set to roll in

31 July 2012

Almirall's aclidinium approved in Europe for COPD maintenance treatment

25 July 2012

US FDA delays approval of Almirall and Forest Laboratories' COPD drug

30 March 2012

Almirall looks to robust 2012 despite higher losses

28 February 2012

FDA panels back Forest and Almirall COPD drug and Chelsea’s Northera for NOH

24 February 2012

Newron updates on deal Meiji Seika Pharma deal; Almirall out-licenses in Korea

14 February 2012

Almirall starts Ph III COPD trial; collaborates with BioFocus; and posts sales and earnings downturn

16 November 2011

Forest and Almirall see early filing of COPD drug aclidinium with US FDA; Appointment at Almirall

4 July 2011

Almirall and Kyorin in 38 million-euro licensing deal for COPD drug in Japan

25 February 2011

Almirall and Forest say their COPD drug aclidinium shows positive results and Ph III and Ph II studies

6 January 2011

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end